-0.58%
1.64%
14.93%
35.54%
75.85%
14.07%
-10.91%
AI Spotlight on PTCT
Company Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.
The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease.PTC Therapeutics, Inc.has collaborations with F.
Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc.to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean.PTC Therapeutics, Inc.
was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Market Data
| Last Price | 45.88 |
| Change Percentage | -0.58% |
| Open | 45.95 |
| Previous Close | 46.15 |
| Market Cap ( Millions) | 3538 |
| Volume | 965575 |
| Year High | 54.16 |
| Year Low | 23.58 |
| M A 50 | 45.36 |
| M A 200 | 37.4 |
Financial Ratios
| FCF Yield | -5.91% |
| Dividend Yield | 0.00% |
| ROE | 48.38% |
| Debt / Equity | -37.96% |
| Net Debt / EBIDTA | 119.06% |
| Price To Book | -3.35 |
| Price Earnings Ratio | -7.79 |
| Price To FCF | -16.92 |
| Price To sales | 3.93 |
| EV / EBITDA | -32.3 |
News
- Jan -13 - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan -13 - PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
- Dec -23 - PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -19 - PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
- Dec -17 - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -03 - PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
- Dec -03 - PTC Therapeutics price target raised to $56 from $45 at Barclays
- Dec -02 - PTC Therapeutics Stock Soars on Novartis Licensing Agreement
- Dec -02 - PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
- Dec -02 - PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
- Dec -02 - PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
- Dec -02 - PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
- Nov -27 - PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
- Nov -27 - PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
- Nov -26 - PTC Therapeutics discontinues development of ALS drug after trial failure
- Nov -26 - PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
- Nov -25 - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -13 - US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
- Nov -13 - PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
- Nov -08 - PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Small Molecule and Gene Therapeutics
Expected Growth : 4.0 %
What the company do ?
Small Molecule and Gene Therapeutics from PTC Therapeutics, Inc. are innovative treatments for rare genetic disorders, using small molecules and gene therapy to address underlying genetic causes.
Why we expect these perspectives ?
PTC Therapeutics' Small Molecule and Gene Therapeutics segment growth is driven by increasing adoption of Translarna for Duchenne muscular dystrophy, expansion into new markets, and a strong pipeline of novel therapies. Additionally, strategic partnerships and collaborations are expected to fuel growth, along with increasing investment in research and development to address unmet medical needs.
Ptc Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| Translarna | A protein synthesis inhibitor for the treatment of nonsense mutations in genetic disorders |
| Emflaza | A corticosteroid for the treatment of Duchenne muscular dystrophy |
| Evrysdi | A survival motor neuron 1 (SMN1) splicing modifier for the treatment of spinal muscular atrophy |
| Waylivra | A treatment for familial chylomicronemia syndrome, a rare genetic disorder |
| Gene therapy platform | A platform for the development of gene therapies for rare genetic disorders |
PTC Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
PTC Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for rare genetic disorders. However, the company's focus on developing novel therapies for unmet medical needs reduces the threat of substitutes.
Bargaining Power Of Customers
PTC Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options for patients with rare genetic disorders.
Bargaining Power Of Suppliers
PTC Therapeutics, Inc. has a moderate bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and manufacturing services. However, the company's strong relationships with suppliers and its diversified supply chain mitigate the risk of supplier concentration.
Threat Of New Entrants
PTC Therapeutics, Inc. has a low threat of new entrants due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development, regulatory approvals, and manufacturing capabilities.
Intensity Of Rivalry
PTC Therapeutics, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company must continually innovate and invest in research and development to stay ahead of its competitors.
Capital Structure
| Value | |
|---|---|
| Debt Weight | -57.92% |
| Debt Cost | 7.07% |
| Equity Weight | 157.92% |
| Equity Cost | 7.07% |
| WACC | 7.07% |
| Leverage | -36.68% |
PTC Therapeutics, Inc. : Quality Control
PTC Therapeutics, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DNLI | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, … |
| CLDX | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with … |
| RYTM | Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is … |
| FOLD | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the … |
| BMRN | BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
PTC Therapeutics
A-Score
1-Year Total Return ->
🥈
Denali Therapeutics
A-Score
1-Year Total Return ->
🥉
BioMarin Pharmaceutical
A-Score
1-Year Total Return ->
4
Amicus Therapeutics
A-Score
1-Year Total Return ->
5
Rhythm Pharma
A-Score
1-Year Total Return ->
6
